Johnson & Johnson vs Qualcomm: Revenue, Profit and Business Model
Johnson & Johnson reported $94.2B of revenue in FY2025 and $26.8B of net income. Qualcomm reported $44.3B of revenue in FY2025 and $5.5B of net income.
Latest financial snapshot
Johnson & Johnson
- Latest revenue
- $94.2B (FY2025)
- Net income
- $26.8B
- Net margin
- 28.5%
- Revenue growth
- +3.0% a year, FY2016–FY2025
Qualcomm
- Latest revenue
- $44.3B (FY2025)
- Net income
- $5.5B
- Net margin
- 12.5%
- Revenue growth
- +7.3% a year, FY2016–FY2025
Financial summary
Johnson & Johnson
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.
Qualcomm
Qualcomm's revenue has swung with the smartphone cycle: $44.2B in FY2022, $35.8B in FY2023, $39.0B in FY2024 and a record $44.284B in FY2025. FY2025 operating income was $12.355B, but GAAP net income dropped to $5.541B because of a large non-cash income tax charge booked in the September 2025 quarter. FY2026 has been tougher on the top line. Q2 revenue was $10.599B, and Q3 revenue fell 4% year over year to $9.9B with GAAP EPS of $1.87 and non-GAAP EPS of $2.21, as higher memory costs squeezed handset demand. QTL revenue was $1.3B in Q3. Qualcomm returned $2.3B to shareholders that quarter and guided Q4 FY2026 revenue to $9.7B-$10.5B.
Revenue and profit by year
Johnson & Johnson
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | +6.0% | Source |
| FY2024 | $88.8B | $14.1B | 15.8% | +4.3% | Source |
| FY2023 | $85.2B | $35.2B | 41.3% | +6.5% | Source |
| FY2022 | $80B | $17.9B | 22.4% | +1.6% | Source |
| FY2021 | $78.7B | $20.9B | 26.5% | -4.7% | Source |
| FY2020 | $82.6B | $14.7B | 17.8% | +0.6% | Source |
| FY2019 | $82.1B | $15.1B | 18.4% | +0.6% | Source |
| FY2018 | $81.6B | $15.3B | 18.8% | +6.7% | Source |
| FY2017 | $76.5B | $1.3B | 1.7% | +6.3% | Source |
| FY2016 | $71.9B | $16.5B | 23.0% | — | Source |
Qualcomm
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $44.3B | $5.5B | 12.5% | +13.7% | Source |
| FY2024 | $39B | $10.1B | 26.0% | +8.8% | Source |
| FY2023 | $35.8B | $7.2B | 20.2% | -19.0% | Source |
| FY2022 | $44.2B | $12.9B | 29.3% | +31.7% | Source |
| FY2021 | $33.6B | $9B | 26.9% | +42.6% | Source |
| FY2020 | $23.5B | $5.2B | 22.1% | -3.1% | Source |
| FY2019 | $24.3B | $4.4B | 18.1% | +7.4% | Source |
| FY2018 | $22.6B | -$5B | -22.0% | +1.6% | Source |
| FY2017 | $22.3B | $2.4B | 11.0% | -5.5% | Source |
| FY2016 | $23.6B | $5.7B | 24.2% | — | Source |
Where the revenue comes from
Johnson & Johnson
- Innovative Medicine~64%
Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.
- MedTech~36%
MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.
Qualcomm
- QCT Handsets~63%
Snapdragon processors, modems and RF chips for smartphones: $27.793B in FY2025. Handset revenue fell 20% to $5.1B in Q3 FY2026 as memory costs hurt phone demand.
- QCT IoT~15%
Chips for industrial devices, networking, XR headsets, PCs and consumer electronics: $6.617B in FY2025 and $1.8B in Q3 FY2026.
- QCT Automotive~9%
Snapdragon Digital Chassis cockpit, ADAS and connectivity platforms: $3.957B in FY2025, up from $2.9B in FY2024, and $1.6B in Q3 FY2026 (up 61%).
- QTL Licensing and other~13%
Royalties on Qualcomm's cellular patents plus smaller strategic initiatives. QTL revenue was $1.3B in Q3 FY2026 at a 69% EBT margin, making it a disproportionate profit contributor.
Business model and strategy
Johnson & Johnson
How it makes money
J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal.
Growth strategy
J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).
Competitive advantage
J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time.
Qualcomm
How it makes money
Qualcomm earns money in two ways. QCT (Qualcomm CDMA Technologies) designs Snapdragon systems-on-chip, modems, RF front-end and Wi-Fi/Bluetooth chips and sells them to handset, automotive, PC and IoT customers; manufacturing is outsourced to foundries such as TSMC and Samsung. QCT produced $38.367B of FY2025 revenue, including $27.793B from handsets, $6.617B from IoT and $3.957B from automotive.
Growth strategy
Qualcomm's growth plan is to reuse Snapdragon's low-power compute, connectivity and AI engines outside phones. Automotive is the clearest win so far, with the Snapdragon Digital Chassis growing from $2.9B in FY2024 to $3.957B in FY2025 and $1.6B in Q3 FY2026 alone. Snapdragon X chips target Windows Copilot+ laptops. Industrial IoT and robotics carry a design-win pipeline above $7B.
Competitive advantage
Qualcomm's edge comes from pairing leading cellular modem and RF engineering with one of the largest portfolios of standard-essential wireless patents. That combination lets it sell integrated Snapdragon platforms (CPU, GPU, NPU, modem and RF) while still collecting royalties on phones that use rival chips. Its custom Oryon CPU cores, from the 2021 Nuvia deal, now run in both flagship phone and Windows PC chips.
Questions about Johnson & Johnson vs Qualcomm
Which company has higher revenue — Johnson & Johnson or Qualcomm Inc.?
Johnson & Johnson reported $94.2B (FY2025), while Qualcomm Inc. reported $44.3B (FY2025). By last reported revenue, Johnson & Johnson is the larger business, with Qualcomm Inc. reporting a smaller revenue base.
What is the market cap of Johnson & Johnson vs Qualcomm Inc.?
Johnson & Johnson's market capitalisation stands at $643.9B, while Qualcomm Inc.'s is $208.0B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Qualcomm Inc..
Which is more financially efficient — Johnson & Johnson or Qualcomm Inc.?
Johnson & Johnson generates $669k / employee in revenue per employee, while Qualcomm Inc. generates $852k / employee. Qualcomm Inc. shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Johnson & Johnson and Qualcomm Inc. make money?
Johnson & Johnson and Qualcomm Inc. generate revenue in fundamentally different ways. Johnson & Johnson: J&J makes money in two ways. Qualcomm Inc.: Qualcomm earns money in two ways.
Which company is valued higher relative to revenue — Johnson & Johnson or Qualcomm Inc.?
On a price-to-sales (P/S) basis, Johnson & Johnson trades at 6.8x P/S and Qualcomm Inc. at 4.7x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Qualcomm Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Johnson & Johnson bigger than Qualcomm Inc.?
By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to Qualcomm Inc. ($44.3B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Johnson & Johnson vs Qualcomm overview